Stockscreener 앱 받기
2.84
1.43%
0.04
시간 외 거래:
2.86
0.02
+0.70%
전일 마감가:
$2.80
열려 있는:
$2.8
하루 거래량:
5.14M
Relative Volume:
1.59
시가총액:
$463.08M
수익:
-
순이익/손실:
$-175.43M
주가수익비율:
-1.439
EPS:
-1.9736
순현금흐름:
$-143.28M
1주 성능:
-6.58%
1개월 성능:
-14.20%
6개월 성능:
+21.89%
1년 성능:
+52.28%
1일 변동 폭
$2.79
$3.09
1주일 범위
$2.77
$3.195
52주 변동 폭
$1.26
$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
명칭
Cabaletta Bio Inc
전화
(267) 759-3100
주소
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.84 | 490.79M | 0 | -175.43M | -143.28M | -1.9736 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 재개 | Jefferies | Buy |
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-02-05 | 개시 | Jefferies | Buy |
| 2023-11-29 | 개시 | William Blair | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | Stifel | Buy |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-07-18 | 개시 | Guggenheim | Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-01-08 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-13 | 개시 | H.C. Wainwright | Buy |
| 2019-11-19 | 개시 | Cowen | Outperform |
| 2019-11-19 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
CABA - Finviz
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options - Stock Titan
Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22 - Stock Titan
Cabaletta Bio (CABA) director Catherine Bollard receives 22,000 stock options at $3.22 - Stock Titan
22,000 options granted to Cabaletta Bio (CABA) director Brun - Stock Titan
Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D - Business Wire
CABA: Rese-cel delivers durable, safe remissions in myositis, supporting rapid outpatient adoption - TradingView
CABA: Rese-cel shows durable, safe, drug-free responses, enabling rapid outpatient adoption and expansion - TradingView
Cabaletta Bio Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases - Yahoo Finance
Jennison Associates LLC Increases Stake in Cabaletta Bio Inc - GuruFocus
Investors’ Stock Portfolio: Top 5 Penny Stocks To Buy - Insider Monkey
Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4% - Stock Titan
CABALETTA BIO INC (CABA) Stock Chart - ChartMill
Jennison Associates (NASDAQ: CABA) holds 24.27M shares, 11.4% - Stock Titan
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cabaletta Bio reports phase 1/2 data for autoimmune therapy - Investing.com UK
Jefferies reiterates Cabaletta Bio stock rating on autoimmune data By Investing.com - Investing.com South Africa
CABA: Cabaletta Bio Shares Positive Clinical Updates at EULAR 20 - GuruFocus
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Highlights Rese-cel Data and Pivotal Path - TipRanks
Jefferies reiterates Cabaletta Bio stock rating on autoimmune data - Investing.com India
Cabaletta Bio reports phase 1/2 data for autoimmune therapy By Investing.com - Investing.com Nigeria
Cabaletta Bio (CABA) details strong rese-cel data and pivotal plans in myositis, SSc and lupus - Stock Titan
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress - The Manila Times
Cabaletta Bio Shares Tick Up Ahead of June Data Investors Await - Bez Kabli
Cabaletta Bio (CABA) Climbs 2.7% as Biotech Stock Tests Key Resistance Near $4.14Low Risk Entry Stocks - thelegaladvocate.com
Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo
CABA Technical Analysis | Trend, Signals & Chart Patterns | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
CABA stock on track for best day in 6 months after positive early results from cell therapy trial - MSN
Cabaletta Reports Drug-Free Responses in CAR-T Study - MyChesCo
Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
CABA Stock Price, Quote & Chart | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - sharewise.com
Guggenheim Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Inc (CABA) Stock Price, Quote, News & History - Benzinga
Cormorant Funds disclose 10.5M-share position in Cabaletta Bio (CABA) - Stock Titan
CABA Maintains Rating by Wells Fargo -- Price Target Raised to $4.00 - GuruFocus
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $16 to $16 - Moomoo
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Cuts Target Price to $3.61 - Moomoo
Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Key facts: Cabaletta Q1 $0.39 Adj Loss, $43.52M Net Loss; ASGCT Data - TradingView
CABA Shows Promising Results in New Clinical Data - GuruFocus
Cabaletta Bio Inc (CABA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cabaletta Bio Inc 주식 (CABA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | President, Science & Tech. |
Jan 21 '26 |
Buy |
2.19 |
11,312 |
24,763 |
31,312 |
| Tomasello Shawn | Director |
Jan 21 '26 |
Buy |
2.21 |
22,725 |
50,322 |
22,725 |
| Gavel Steve | Chief Commercial Officer |
Jan 21 '26 |
Buy |
2.27 |
22,170 |
50,215 |
22,170 |
| Bollard Catherine | Director |
Jan 21 '26 |
Buy |
2.27 |
4,405 |
9,982 |
5,405 |
| Nichtberger Steven | President & CEO |
Jan 21 '26 |
Buy |
2.24 |
45,000 |
100,778 |
1,031,483 |
| Simon Mark | Director |
Jan 21 '26 |
Buy |
2.28 |
11,061 |
25,261 |
147,205 |
| Gerard Michael | General Counsel |
Jan 21 '26 |
Buy |
2.27 |
6,600 |
14,979 |
6,600 |
2.60%
0.94%
자본화:
|
볼륨(24시간):